copovithane

01/01/1986 - "However, copovithane does penetrate well to tumor tissues, achieving high tumor/plasma ratios. "
01/01/1986 - "In concert with its phase I clinical trial, copovithane concentrations were analyzed by HPLC in plasma, urine, and autopsy and in tumor biopsy specimens obtained from patients. "
08/01/1986 - "Ninety-one patients with various metastatic neoplasms beyond the curable stage were treated with copovithane by weekly intravenous administration. "
04/01/1987 - "Thirty patients with advanced colorectal carcinoma with measurable tumors were treated in an open randomized study with two schedules of copovithane (schedule A: 6 g/m2 i.v. over 30 min daily for 5 consecutive days and repeated every 3 weeks; schedule B: 10 g/m2 i.v. over 30 min once a week until progression, unacceptable toxicity, or up to 18 months). "
01/01/1986 - "Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer."

01/01/1989 - "Copovithane (CPV), a synthetic polymer, has been shown to have antitumor activity and also to reduce mortality in experimental murine peritonitis. "
05/01/1985 - "Enhanced survival in antibiotic-treated murine fecal peritonitis by administration of copovithane, a selective immunostimulative polymer."
05/01/1985 - "The purpose of this study was to determine the effect of an immunostimulative polymer, Copovithane (Cpv), plus antibiotics (netilmicin and clindamycin) in a murine model of fecal peritonitis. "

04/01/1987 - "Copovithane was ineffective against colorectal carcinoma by both schedules selected in this study."
04/01/1987 - "A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma."
04/01/1987 - "Thirty patients with advanced colorectal carcinoma with measurable tumors were treated in an open randomized study with two schedules of copovithane (schedule A: 6 g/m2 i.v. over 30 min daily for 5 consecutive days and repeated every 3 weeks; schedule B: 10 g/m2 i.v. over 30 min once a week until progression, unacceptable toxicity, or up to 18 months). "

01/01/1989 - "Evaluation of copovithane as a nonspecific immunomodulator in surgically simulated sepsis."